Takeda Pharmaceutical Li... (TAK)
14.30
0.42 (3.03%)
At close: Apr 14, 2025, 3:21 PM
3.03% (1D)
| Bid | 14.3 |
| Market Cap | 45.35B |
| Revenue (ttm) | 4,546.1B |
| Net Income (ttm) | 290B |
| EPS (ttm) | 0.44 |
| PE Ratio (ttm) | 32.51 |
| Forward PE | 25.27 |
| Analyst | n/a |
| Ask | 14.31 |
| Volume | 1,349,085 |
| Avg. Volume (20D) | 1,952,255 |
| Open | 14.17 |
| Previous Close | 13.88 |
| Day's Range | 14.14 - 14.32 |
| 52-Week Range | 12.58 - 15.37 |
| Beta | 0.34 |
About TAK
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Reves...
Sector Healthcare
IPO Date Jan 5, 2010
Employees 49,281
Stock Exchange NYSE
Ticker Symbol TAK
Website https://www.takeda.com
1 month ago
+2.98%
Takeda Pharmaceutical shares are trading higher af...
Unlock content with
Pro Subscription
2 months ago
+2.93%
Takeda Pharmaceutical shares are trading higher after the company reported better-than-expected Q3 sales results. Also, the company announced a new CEO and share buyback program.
6 days ago · accessnewswire.com
BioInvent Receives Milestone Payment as Takeda moves mezagitamab into Phase 3LUND, SWEDEN / ACCESS Newswire / April 8, 2025 / BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech company focused on the discovery and development of novel and first-in-clas...
